Skip to main content
. 2021 Jul 2;43(6):1693–1704. doi: 10.1007/s11096-021-01302-6

Table 2.

Rationale for pharmacist interventions

Intervention category Subcategory Reasons for intervention n (%) Examples of interventions made by pharmacists
Quantity of drug, 26.5%, n = 182 Dose change Age 38 (16.7)

Rivaroxaban dose reduced to 15 mg OD as recorded GFR 29 (CrCl 49)

Edoxaban dose increased to 60 mg OD as eGFR improved (GFR 62, CrCl > 50 ml/min)

Changed from dabigatran 150 mg to 110 mg to match medicines reconciliation

Renal function 67 (29.4)
Weight 41 (18.0)
Adverse effect (bleeding) 2 (0.9)
Pre-admission dose 9 (3.9)
Indication/per guidelines 30 (13.2)
To match medicine reconciliation 10 (4.4)
Not specified 31 (13.6)
Total 228*
Change schedule Total 1 Apixaban timings altered so patient wouldn’t miss a day of treatment
Change duration of treatment Per guidelines 7 (46.7) Apixaban duration of loading dose corrected to 7 days
Not specified 8 (53.3)
Total 15
Pharmacological strategy, 38.1%, n = 262 Drug change Interaction 7 (12.7)

Interaction between voriconazole and apixaban. Patient to be switched to warfarin

Advised doctor that apixaban less effective if weight > 120 kg, warfarin more suitable

Apixaban switched to enoxaparin due to swallowing issues

Tinzaparin switched to edoxaban to improve compliance post-discharge

Surgery 3 (5.5)
More effective option available 2 (3.6)
Renal function 7 (12.7)
Per history (Hx) 6 (10.9)
Dysphagia 2 (3.6)
Aid compliance 1 (1.8)
Not specified 27 (49.1)
Total 55
Change administration Dysphagia 4 (66.7) Rivaroxaban paused due to dysphagia. Advised that the patient could continue, crush and disperse in water
Other 2 (33.3)
Total 6
Start/restart medication Pre-admission 25 (18.5)

Proposed pre-admission dabigatran

Proposed rivaroxaban to start 72 h post-surgery as per procedure

Newly diagnosed AF. Team to consider starting apixaban + anticoagulation referral

Discharge 30 (22.2)
Post-procedure 9 (6.7)
Diagnosis 10 (7.4)
Post-scan 4 (3.0)
Not specified 57 (42.2)
Total 135
Medication paused Surgery 9 (31.0)

Advised to stop edoxaban for 24-48 h prior to surgery

Apixaban was being withheld as patient has a subdural haematoma

Patient at high risk of falling—apixaban paused

Reduced renal function 5 (17.2)
Active bleeding 3 (10.3)
Fall risk 2 (6.9)
Vomiting 1 (3.4)
Not specified 9 (31.0)
Total 29
Discontinue medication Interaction 1 (3.4)

Asked doctor to remove Ibuprofen from TTO due to high risk of bleeding with Apixaban

Apixaban stopped due to small subarachnoid haemorrhage

Rivaroxaban stopped due to risk of falls

Duplicate therapy 3 (10.3)
Active bleeding 4 (13.8)
Bleeding risk 2 (6.9)
Fall risk 1 (3.4)
Renal impairment 3 (10.3)
Not indicated 3 (10.3)
Not specified 12 (41.4)
Total 29
Monitoring Interaction 3 (37.5)

Apixaban needs reviewing, patient’s LFTs not within range – Doctor to monitor

Advised GP to review renal function in one week’s time to check GFR

Liver impairment 1 (12.5)
Monitor renal function 1 (12.5)
Intolerance 1 (12.5)
Other 2 (25.0)
Total 8
Patient education, 14.5%, n = 100 Enhance compliance Change dosing regime 1 (50.0) Advised to see if switching from apixaban 10 mg OD to rivaroxaban is an option to help with compliance without imposing a risk
Patient refusal to take medicine 1 (50.0)
Total 2
Newly initiated Diagnosis 3 (15.8) Conversation with patient about change from apixaban to edoxaban, patient thought 60 mg (edoxaban) was too high a dose in comparison to 5 mg (apixaban)
Drug change 2 (10.5)
Not specified 14 (73.7)
Total 19
General counselling Total 79
Documentation, 9.7%, n = 67 Update drug record Document end date 1 (6.3) Informed doctor of patient’s regular medications to be charted, including apixaban
Amend drug 2 (12.5)
Amend dose 4 (25.0)
Drug missing from chart 5 (31.3)
Other 4 (25.0)
Total 16
Update discharge letter Drug change 4 (30.8) Discharge letter needed to be updated to include that warfarin has been switched to apixaban
Amend dose 3 (23.1)
Other 6 (46.2)
Total 13
Indication Total 23 Confirmed indication for apixaban as not clearly documented in the discharge letter
Thrombosis assessment update Total 15 Thrombosis assessment—contraindication to enoxaparin as patient on rivaroxaban
Other, 11.2%, n = 77 Book follow-up appointment Total 5 Advised doctor that the patient was new to apixaban and will need anticoagulation appointment referral on discharge
Check dose Doesn’t comply with guidelines 4 (18.2) Queried why lower dose of apixaban prescribed as patient did not meet criteria for dose reduction in AF
Subtherapeutic 7 (31.8)
Renal function 4 (18.2)
Other 7 (31.8)
Total 22
Consult prescriber Rational for drug change 2 (4.0)

Queried with the doctor about restarting rivaroxaban as bleeding has settled

Discussed with doctor about restarting apixaban—renal function shows slight improvement

When to restart drug 14 (28.0)
Rational for drug choice 4 (8.0)
Rational for drug discontinuation 3 (6.0)
Rational for duplicate therapy 12 (24.0)
Query drug duration 1 (2.0)
Review plan 14 (28.0)
Total 50

*The total number of reasons for dose change does not equal the number of dose change intervention cases (n = 166) due to multifactorial rationale (i.e., dose change for one patient due to both age and weight); AF atrial fibrillation, GFR glomerular filtration rate, GP general practitioner, LFTs liver function test, OD once daily’ TTO to take out (prescriptions)